This article is more than 5 years old. Information may no longer be current.

FDA approves silicone hydrogel from Lagado

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Lagado Corp., a wholly owned subsidiary of Menicon America Inc., has received U.S. Food and Drug Administration clearance for Lagado LSH (mangofilcon A), a new silicone hydrogel material for use in contact lenses, the company said in a press release.

The material has a midrange water content (49%), and Lagado LSH lenses will be plasma oxidized to produce a low wetting angle and improved wettability, which promotes lens comfort, improves visual performance and reduces the potential for deposits, according to the release.

The company will now begin working closely with a select group of independent, custom lens laboratories in the U.S. Each lab is required to submit and receive FDA clearance for lenses offered in the Lagado LSH material, the release said.

The company anticipates Lagado LSH lenses becoming available later this year, according to the release.